This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We collaborated with Dr. Hans Schreiber at the University of Chicago in the identification of a unique tumor antigen, which is believed to result from aberrant glycosylation. Dr. Schreiber had generated a monoclonal antibody, 237mAb, which specifically recognizes a type I membrane protein, OTS8, expressed in Ag104A, a highly aggressive murine tumor. The 237mAb antibody does not bind to any other tissue or tumor cell line tested, not even those expressing high levels of OTS8. Sequencing of OTS8 from Ag104A did not reveal any mutations, suggesting that the uniqueness of the antigen is probably due to posttranslational modification.
Showing the most recent 10 out of 104 publications